ITPP(Myo-inositolTrispyrophosphate) CAS NO.802590-64-3

Detailed introduction to myo-Inositol tripyrophosphate, ITPP, 802590-64-3,:

Please send me the email address by the message!!! Many thanks!!!

Registry Number:            802590-64-3

Formula:                        C6 H12 O21 P6

CA Index Name:             myo-Inositol, cyclic 1,2:3,4:5,6-tris(P,P'-dihydrogen diphosphate)

Other Names:                 ITPP; myo-Inositol 1,6:2,3:4,5 tripyrophosphate

Myo-inositol trispyrophosphate (ITPP), A synthetic allosteric effector of hemoglobin, increases the regulated oxygen-releasing capacity of red blood cells(RBCs) for an effective straight for the horse or greyhound to run faster.

Abstract
A major determinant of maximal exercise capacity is the delivery of oxygen to exercising muscles. myo-Inositol trispyrophosphate (ITPP) is a recently identified membrane-permeant molecule that causes allosteric regulation of Hb oxygen binding affinity. In normal mice, i.p. administration of ITPP (0.5–3 g/kg) caused a dose-related increase in the oxygen tension at which Hb is 50% saturated (p50), with a maximal increase of 31%. In parallel experiments, ITPP caused a dose-related increase in maximal exercise capacity, with a maximal increase of 57 ± 13% (P = 0.002). In transgenic mice with severe heart failure caused by cardiac-specific overexpression of Gαq, i.p. ITPP increased exercise capacity, with a maximal increase of 63 ± 7% (P = 0.005). Oral administration of ITPP in drinking water increased Hb p50 and maximal exercise capacity (+34 ± 10%; P < 0.002) in normal and failing mice. Consistent with increased tissue oxygen availability, ITPP decreased hypoxia inducible factor-1α mRNA expression in myocardium. It had no effect on myocardial contractility in isolated mouse cardiac myocytes and did not affect arterial blood pressure in vivo in mice. Thus, ITPP decreases the oxygen binding affinity of Hb, increases tissue oxygen delivery, and increases maximal exercise capacity in normal mice and mice with severe heart failure. ITPP is thus an attractive candidate for the therapy of patients with reduced exercise capacity caused by heart failure.